drugset / Trial / NCT01757691

Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

NCT01757691

Phase 2 Terminated 2 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment

Timeline

Start
2013-08
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg Oral

Indications